Ro 6-3129
 | |
| Clinical data | |
|---|---|
| Other names | 16α-Ethylthiodydrogesterone; 16α-Ethylthio-6-dehydroretroprogesterone; 16α-Ethylthio-9β,10α-pregna-4,6-diene-3,20-dione |
| Routes of administration | Oral |
| Identifiers | |
| |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C23H32O2S |
| Molar mass | 372.57 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ro 6-3129, also known as 16α-ethylthio-6-dehydroretroprogesterone or as 16α-ethylthio-9β,10α-pregna-4,6-diene-3,20-dione, as well as 16α-ethylthiodydrogesterone, is a progestogen of the retroprogesterone group which was developed by Roche but was never marketed.[1][2][3] It shows greater potency than dydrogesterone in bioassays.[4]
References
- ^ JUCKER (8 March 2013). Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des rechersches pharmaceutiques. Birkhäuser. pp. 321–. ISBN 978-3-0348-7098-6.
- ^ Larsson-Cohn U, Johansson ED, Wide L, Gemzell C (1970). "Effects of daily administration of a retrosteroid on the plasma levels of progesterone and on the urinary excretion of luteinizing hormone and total oestrogens". J Obstet Gynaecol Br Commonw. 77 (9): 840–6. doi:10.1111/j.1471-0528.1970.tb04411.x. PMID 5458777. S2CID 6176278.
- ^ Dixon, Ross; Hudson, Sean; Darragh, Austin (1973). "Pharmacokinetics of the retro-steroid progestogen, 16α-ethylthio-9β,10α-pregna-4, 6-diene-3, 20-dione (Ro 6-3129), in man and the sheep". Contraception. 8 (1): 53–65. doi:10.1016/0010-7824(73)90159-5. ISSN 0010-7824.
- ^ The Journal of Obstetrics and Gynaecology of the British Commonwealth. Royal College of Obstetricians and Gynaecologists. 1970.
 | This article about a steroid is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |